Colorectal cancer
PRINCIPAL INVESTIGATORS
- Mercedes Martinez Villacampa
- Cristina Santos Vivas
- Gemma Soler González
- Eric Jeffrey Duell
CLINICAL RESEARCHERS
- Francisco Rodríguez Moranta
- Ferran Losa Gaspà
- Albert Sueiras Gil
- Mireia Obon Santacana
- Esther Kreisler Moreno
- Jose Carlos Ruffinelli Rodríguez
- Doménico Nicola Fraccalvieri
POSTDOCTORAL RESEARCHERS
- Marisa Martínez Muñoz
- Alba Magallon Baro
- Elies Ramon Gurrea
- Gemma Ibañez Sanz
- Nuria Moragas Garcia
- Miguel Socolovsky Visiedo
- Francisco David Moron Duran
- Claudia Monica Aura Gonzalez
- David Bars Cortina
Ditsuhi Iskandaryan
PREDOCTORAL RESEARCHERS
- Blanca Rius Sansalvador
- Lois Riobo Mayo
SCIENTIFIC SUPPORT
- Eduardo Delgado De La Iglesia
- Anna Diez Villanueva
- Susana Lopez Ruiz
- Catalina Medici
- Elisabet Guino Domenech
- Ferran Moratalla Navarro
- Carmen Rosa Atencia Rojas
MANAGEMENT SUPPORT
- Thiago Carnaval
- Mario Amigo Garcia
- Jordi Vea Barbany
- Adelaida Piera Sancerni
- Silvia Murcia Muñoz
- Olga Lopez Ciercoles
- Paula Ximena Fernandez Calotti
- Camille Martine Marie Frey
- Catalina Isabel Cofre Muñoz
Cancer
Oncobell
Scientific production
74
PAPERS
Average IF: 8,825
22
LED PAPERS
Average IF: 4,005
16 PUBLICATIONS IN FIRST DECILE
43 PUBLICATIONS IN FIRST QUARTILE
58 PUBLICATIONS IN OPEN ACCESS
Selected publications:
- Cortellini,A;Tabernero,J;Mukherjee,U;Salazar,R;Sureda,A;Maluquer,C;Ferrante,D et al, SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry, Lancet Oncol., 2023;24(4):335-346, doi:10.1016/S1470-2045(23)00056-6
- Tagliamento,M;Gennari,A;Lambertini,M;Salazar,R;Harbeck,N;Del Mastro,L;Aguilar Company,J et al, Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer, J. Clin. Oncol., 2023;41(15):2800-2814 doi:10.1200/JCO.22.01667
- Van Cutsem,E;Taieb,J;Yaeger,R;Yoshino,T;Grothey,A;Maiello,E;Elez,E et al, ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer., J. Clin. Oncol., 2023;41(14):2628-2637, doi:10.1200/JCO.22.01693
- Fernandez Rozadilla,C;Timofeeva,M;Chen,Z;Law,P;Thomas,M;Schmit,S;Díez Obrero,V et al, Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries., Nature Genet., 2023;55(1):89-99, doi:10.1038/s41588-022-01222-9
- Mahmood,K;Thomas,M;Qu,C;Gecco Ccfr,C;Hsu,L;Buchanan,DD;Peters,U, Elucidating the Risk of Colorectal Cancer for Variants in Hereditary Colorectal Cancer Genes., Gastroenterology, 2023;165(4):doi:10.1053/j.gastro.2023.06.032
Research highlights
PROJECTS
2 Granted competitive projects
24 Ongoing competitive projects
11 Started clinical trials
39 Ongoing clinical trials
PUBLISHED WORKS
3 Clinical guidelines
NETWORKS
CIBERESP
ECPC
SGR GRC
PERSIST
ML4 Microbiome
GECCO
UNCAN
Selected projects
- MCI21055. Federación de datos de salud: identificación inteligente de factores compartidos entre cáncer y enfermedades cardiovasculares para la mejorar prevención a lo largo de la vida (CC-Shared). Ministerio de Ciencia e Innovación. Budget: 524.400€. 2022-2024. PI: MORENO AGUADO, VICTOR RAUL.
- 18PSJ019. Genetic and metabolomics screening towards the precision medicine in cancer prevention (Genrisk). Asociación Española Contra el Cáncer (AECC). Budget: 500.000€. 2018-2024. PI: MORENO AGUADO, VICTOR RAUL.
- ERA21001. IMAGene: Epigenomic and machine learning models to predict pancreatic cancer: development of a new algorithm to integrate clinical, omics, DNA methylation biomarkers and environmental data for early detection of pancreatic cancer in high-risk individuals. Instituto de Salud Carlos III (ISCIII)/Asociación Española Contra el Cáncer (AECC). Budget: 304.687,96€. 2022-2025. PI: MORENO AGUADO, VICTOR RAUL.
- ERA21004. TANGERINE: Artificial-intelligence-based end-to-end prediction of cancer immunotherapy response. Instituto de Salud Carlos III (ISCIII) / Asociación Española Contra el Cáncer (AECC). Budget: 296.341€. 2022-2025. PI: MORENO AGUADO, VICTOR RAUL.
- 20FIS019. Refining the consensus molecular subtypes classification: prognostic and therapeutic implications in stage II colon cancer.. Instituto de Salud Carlos III (ISCIII). Budget: 159.720€. 2020-2024. PI: Salazar Soler, Ramón.